Wealth Effects’s Akebia Therapeutics AKBA Stock Holding History

Wealth Effects’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.7K	Sell	12,000 -4,000	-25%	-$4.76K	﹤0.01%	255
2026 Q1	$22.2K	Hold	16,000	–	–	0.01%	235
2025 Q4	$25.8K	Hold	16,000	–	–	0.01%	216
2025 Q3	$43.7K	Sell	16,000 -18,500	-54%	-$61.5K	0.01%	216
2025 Q2	$126K	Buy	34,500 +2,500	+8%	+$6.87K	0.05%	196
2025 Q1	$61.4K	Hold	32,000	–	–	0.03%	196
2024 Q4	$60.8K	Buy	32,000 +5,000	+19%	+$8.68K	0.02%	209
2024 Q3	$35.6K	Hold	27,000	–	–	0.01%	214
2024 Q2	$27.5K	Hold	27,000	–	–	0.01%	205
2024 Q1	$49.4K	Sell	27,000 -2,500	-8%	-$4K	0.02%	214
2023 Q4	$36.6K	Hold	29,500	–	–	0.01%	225
2023 Q3	$33.6K	Buy	29,500 +11,184	+61%	+$14.4K	0.02%	190
2023 Q2	$16.8K	Hold	18,316	–	–	0.01%	199
2023 Q1	$10.3K	Hold	18,316	–	–	0.01%	197
2022 Q4	$10.6K	Hold	18,316	–	–	0.01%	191
2022 Q3	$6K	Hold	18,316	–	–	﹤0.01%	183
2022 Q2	$6K	Sell	18,316 -512	-3%	-$215	﹤0.01%	188
2022 Q1	$14K	Buy	+18,828	New	+$40.3K	0.01%	203

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wealth Effects's AKBA Position: Q2 2026 in Review

Wealth Effects reduced its Akebia Therapeutics (AKBA) stake by 25% in Q2 2026, selling an estimated $4.76K and leaving 12,000 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #255.

Wealth Effects first reported a position in AKBA in Q1 2022 and has held it in 18 quarters since. The position peaked at $126K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Wealth Effects held 12,000 shares of Akebia Therapeutics worth $13.7K as of Q2 2026.
Wealth Effects sold 4,000 Akebia Therapeutics shares in Q2 2026, an estimated $4.76K.
Akebia Therapeutics made up ﹤0.01% of Wealth Effects's portfolio in Q2 2026, its #255 holding.
Wealth Effects first reported a position in Akebia Therapeutics in Q1 2022 and has held it in 18 quarters since.
Wealth Effects's Akebia Therapeutics position peaked at $126K in Q2 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Wealth Effects's 13F filing for Q2 2026, filed 6 Aug 2026.